Samuel David

Title: Innovations of Samuel David in Pharmaceutical Chemistry

Introduction

Samuel David is an accomplished inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds that target human receptors.

Latest Patents

Samuel David holds a patent for "Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors." This invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives that act as agonists on human ORL1 (nociceptin) receptors. The patent also covers the preparation of these compounds, pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel derivatives, and their use in treating disorders involving ORL1 receptors. He has 1 patent to his name.

Career Highlights

Samuel David is currently employed at Solvay Pharmaceuticals B.V., where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing new therapeutic agents that can improve patient outcomes.

Collaborations

Throughout his career, Samuel has collaborated with notable colleagues, including Jacobus A J Den Hartog and Daniel Jasserand. These collaborations have further enhanced his research and development efforts.

Conclusion

Samuel David's innovative work in pharmaceutical chemistry, particularly his patented compounds targeting ORL1 receptors, showcases his commitment to advancing medical science. His contributions are significant in the ongoing quest for effective treatments for various disorders.